• HyperScribe T7 High Yield Cy3 RNA Labeling Kit: Optimizin...

  2025-09-30

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit streamlines in vitro transcription RNA labeling, enabling high-yield, customizable fluorescent probe synthesis for advanced gene expression and hybridization assays. Its optimized chemistry and workflow flexibility make it the benchmark for generating highly sensitive, Cy3-labeled RNA probes—powering innovations in tumor-selective mRNA research, spatial transcriptomics, and noncoding RNA mapping.

• MLN4924: Unraveling Non-Cullin Neddylation and mTORC1 Sig...

  2025-09-29

  Explore how MLN4924, a potent NEDD8-activating enzyme inhibitor, is redefining cancer biology research by targeting non-cullin neddylation and the mTORC1 pathway. This article provides a unique, in-depth analysis of MLN4924’s mechanism, its impact on tumorigenesis, and its distinct value for anti-cancer therapeutic development.

• Eltanexor (KPT-8602): Transforming Hematological and Soli...

  2025-09-28

  Explore how Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, is advancing cancer research through targeted nuclear export inhibition. This in-depth analysis uniquely examines Eltanexor's impact on caspase signaling and Wnt/β-catenin modulation in both hematological malignancies and colorectal cancer.

• EZ Cap™ EGFP mRNA (5-moUTP): Engineering Precision for Sy...

  2025-09-27

  Explore how EZ Cap™ EGFP mRNA 5-moUTP advances in vivo mRNA delivery and translation efficiency with a Cap 1 structure and 5-moUTP modifications. This article provides a deep dive into mechanism, nanoparticle integration, and future directions for enhanced green fluorescent protein mRNA technologies.

• RSL3 as a Precision Tool: Exploiting Ferroptosis and Redo...

  2025-09-26

  Explore how RSL3, a potent glutathione peroxidase 4 inhibitor, unlocks targeted ferroptosis and iron-dependent cell death in RAS-driven cancers. This article uniquely dissects ferroptosis mechanisms, contrasts apoptotic and non-apoptotic death pathways, and offers advanced insights beyond current literature.

• SM-102 in Lipid Nanoparticles: Systems Biology and Precis...

  2025-09-25

  Explore the systems-level impact of SM-102 in lipid nanoparticles (LNPs) for mRNA delivery and vaccine development. This article uniquely integrates molecular, cellular, and predictive modeling perspectives to unveil new opportunities for precision mRNA therapeutics.

• ISRIB (trans-isomer): Advanced Strategies for Targeting t...

  2025-09-24

  Explore ISRIB (trans-isomer), a potent integrated stress response inhibitor, and its cutting-edge applications in ER stress research, liver fibrosis, and neurodegenerative models. This article reveals nuanced mechanisms and experimental strategies that set new standards for ISR pathway intervention.

• Sildenafil Citrate: Deciphering Proteoform-Specific Signa...

  2025-09-23

  Explore how Sildenafil Citrate, a selective cGMP-specific phosphodiesterase type 5 inhibitor, enables advanced research into proteoform-specific signaling, vascular smooth muscle relaxation, and apoptosis regulation. This article highlights emerging strategies for integrating proteomics and small-molecule pharmacology to elucidate PDE5-related pathways.

• S63845: Targeting MCL1 to Unlock Synergistic Apoptosis Pa...

  2025-09-22

  This article explores the mechanistic synergy between the small molecule MCL1 inhibitor S63845 and extrinsic apoptosis modulators, highlighting its role as a mitochondrial apoptotic pathway activator in cancer research. Focus is placed on recent data supporting combinatorial strategies and on practical considerations for hematological and solid tumor models.

• BMN 673 (Talazoparib): Advancing PARP1/2 Inhibitor Resear...

  2025-09-19

  Explore the latest insights into BMN 673 (Talazoparib), a potent PARP1/2 inhibitor, and its unique role in targeting DNA repair deficiencies and homologous recombination-deficient cancers. This article discusses new mechanistic findings and research applications for selective PARP inhibitors in cancer therapy.

• Phenacetin in Human Intestinal Organoid Models: Research ...

  2025-09-18

  Explore the use of Phenacetin (N-(4-ethoxyphenyl)acetamide), a non-opioid analgesic, in advanced pharmacokinetic studies utilizing human intestinal organoids. This article discusses scientific research applications, solubility characteristics, and safety considerations for Phenacetin.

• br Hyperadiponectinemia in disease conditions Other evidence

  2025-03-03

  

  Hyperadiponectinemia in disease conditions Other evidence indicates that hyperadiponectinemia does not necessarily always imply a healthy outcome. Indeed, a recent study suggested that hyperadiponectinemia occurs in various diseases. Given that the risk for AD and vascular dementia is increased i

• hydroxydopamine OHDA is a selective catecholaminergic neurot

  2025-03-03

  

  6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and

• br Experimental section br Conflicts

  2025-03-03

  

  Experimental section Conflicts of interest Acknowledgments This work was partly supported by INSA-Rouen, Rouen University, CNRS, Labex SynOrg (ANR-11-LABX-0029), Région Haute-Normandie. Introduction A key component of the integrated management of key pests such as codling moth (Cydia po

• An alternative to the agonist or antagonist potential in

  2025-03-03

  

  An alternative to the agonist or antagonist potential in drug discovery is the positive allosteric modulator (PAM) approach, which can augment the normal processes of neurotransmission as opposed to directly replacing or antagonizing them. PAMs are thought to bind to sites that are distinct from the

15958 records 1/1064 page Next 12345 下5页 Last page